Cathie Wood: This Stock Will 50X And Outperform Tesla Stock (BIG INVESTMENT OPPORTUNITY)

Hey everybody today we are gonna understand the genomics and look at the best genomic stocks that we should buy right now which could go up 20-50x in the next 5 years. And I know 50x seems a lot but tesla just went up almost 10 times in just one year. And the main reason why we should understand genomics before investing in them is it is important to understand the purpose of a company. With tesla I knew that tesla was bringing about a massive change in the world a shift to electric cars, which is why it was very easy for me to bet on tesla. I bought tesla at $400 a share and today though the stock is very volatile my position has more than doubled and I’m not looking to sell because I know the purpose of tesla and I believe in it and when I understood genomics I knew this could bring a lot of changes to the world and help to treat a lot of diseases so when you believe in something its easy to bet on it. So lets understand genomics.

So genomics is the study of the genomes inside of us. Let's understand human genomics. Everybody on the planet has a genome that has governed their development and governs a lot of their biology, and as you can see by looking at any crowd of people, we all look really different. However we've discovered in recent years that we're actually 99.9% identical or even more than that. So it's really remarkable how much diversity you can create from a very small number of changes in your genome. But of course, now that we know that we're 99.9% identical, we still want to know, what is it that's driving all these differences?


Why is one person tall and another person short? Why does one person live to be 100 an another person lives to be not 100? Why does one person get cancer and another person not? Many of these things we suspect are driven by our genomes, and we want to understand that. So, another thing, one of the most basic things that our genome determines is how our bodies develop. We start off, as you all know, we start off as a single cell which divides into a few apparently identical cells, but that quickly divides into an embryo, and eventually grows into a whole person.


Another big area of research in genomics is cancer. So cancer is essentially a genetic disease, we know now. Cancer cells are simply, again, cells in your body that have the same genetic code, the same genome in them, but somehow they've gone haywire, and they've started replicating without control. That's what makes something cancerous. Basically it's cells that are dividing without any check on their division. And, in fact, we define cancers by the type of cell that started the cancer. So there's skin cancer, where a skin cell starts dividing without control

Crispr Therapeutics (NASDAQ: CRSP) is the second-largest holding in ARKG and the third-largest holding in ARKK, representing one of the biggest bets Wood has placed on genomics. The company is one of several gene-editing companies.
Editas Medicine (NASDAQ: EDIT), a genome editing company, is another stock Wood owns in both these ETFs.
Invitae Corporation (NYSE: NVTA), a genetics testing company, is a top five holding in both ARKG and ARKK.
Twist Bioscience (NASDAQ: TWST) is the fourth-largest holding in ARKG and a top 15 holding in ARKK. The company makes synthetic DNA and could see strong growth in the market.


please subscribe to my channel !
#Tesla #TeslaStock #arkinvest

Visuals
How Elon Musk Took Tesla To Hell And Back With The Model 3 | CNBC Documentary
https://www.youtube.com/watch?v=QIt8WuEQntY&t=2s

Music

Vacation by Markvard https://soundcloud.com/markvard
Creative Commons — Attribution 3.0 Unported — CC BY 3.0
Free Download / Stream: https://bit.ly/al-vacation
Music promoted by Audio Library https://youtu.be/nxYoIurjLX8
––––––––––––––––––––––––––––––